Latest Bristol Myers Squibb News & Updates

See the latest news and media coverage for BMS. We track all announcements, press releases, and industry mentions in real time, all in one place.

Bristol Myers Squibb (BMS)

Global biopharmaceutical company

bms.com

Headquarters: Lawrence Township, United States
Company type: Public company
Number of employees: 35,000+

Last updated Today

Latest news about Bristol Myers Squibb (BMS)

In short: BMS reported strong Q1 2026 financial growth and achieved several regulatory milestones, including European approval for Sotyktu and Opdivo.

Company announcements

June 2 BMS

BMS's iza-bren shows significant survival benefit in two cancers

The dual-targeted ADC met primary endpoints in two Phase 3 trials, showing statistically significant OS and PFS improvements.

June 1 BMS

BMS receives FDA priority review for Camzyos sNDA in adolescents

If approved, it would be the first pharmacological therapy for adolescent oHCM with a safety profile similar to adults.

June 1 BMS

BMS announces EU approval of Opdivo combination for Hodgkin lymphoma

The first immunotherapy regimen approved in Europe for frontline advanced classical Hodgkin lymphoma in adults and adolescents aged 12 and older.

May 30 BMS

BMS reports encouraging efficacy data for pumitamig in NSCLC trial

The PD-L1xVEGF-A bispecific showed high response rates across subtypes and PD-L1 levels in ROSETTA Lung-02.

Media coverage

June 18 Business Wire

Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026

About Bristol Myers Squibb: ... At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious...

June 18 Yahoo Finance

Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes

Bristol-Myers Squibb (BMY) stock is drawing attention after recent trading performance, with shares closing at US$55.28.

June 17 Yahoo Finance

EHA26: BMS touts positive multiple myeloma data for two pipeline candidates

Bristol Myers Squibb (BMS) has revealed clinical data for two pipeline candidates in multiple myelom...

June 17 Dermatology Times

BMS Pursues Global Approval for Deucravacitinib for PsA | Dermatology Times

Bristol Myers Squibb’s supplemental new drug application (sNDA) for sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis accepted for review across four...

Never miss news about BMS

Track BMS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BMS competitors & trending companies

Browse news for competitors to BMS and other trending companies.